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Abstract
Introduction
Hepatic osteodystrophy is an osteoporotic bone disease that occurs in chronic liver disease patients. The
global prevalence of osteoporosis in patients with chronic liver disease is 30% to 40%. The pathogenesis of
hepatic bone disease is not clear, but it occurs due to unstable bone remodeling with increased bone
resorption and decreases bone formation. There has been an interest in determining the clinical utility of
bone turnover markers (BTMs) in the assessment of osteoporosis in chronic liver patients.
Methods
This was a cross-sectional study conducted in patients with chronic liver disease at the section of chemical
pathology, department of pathology and laboratory medicine, Aga Khan University (AKU). A total of 50
patients with age >8 years and a history of liver disease >6 months were recruited from January to October
2019. Liver function tests, i.e. aspartate aminotransferase (AST), alanine transaminase (ALT), albumin, and
bilirubin, along with clinical signs of liver disease chronicity, were noted. The samples for BTMs, i.e. total
serum alkaline phosphatase (ALP) and serum C-terminal telopeptide of type-1 collagen (CTX) were
withdrawn and analyzed on Microlab (ELItech Group, Puteaux, France) and ADVIA Centaur (Siemens
Diagnostics, NY), respectively.
Results
The majority of patients were males (n=34, 68%). Twenty-four (48%) patients suffered from fibrosis while 26
(52%) were without fibrosis. Median platelet count (68×109/L (102.5-50)) and median cholesterol levels
(102.5 mg/dl (147-99.5)) were decreased, whereas gamma-glutamyl transferase (GGT) levels were higher in
the fibrosis group as compared to the non-fibrosis group. The median levels of total ALP were 91.5 IU/L (103-
82), and the median levels of CTX were 0.24 pg/ml (0.34-0.21).
Conclusion
In the present study, no significant difference was found in the BTMs of patients with and without chronic
liver disease (CLD). However, there was a positive and significant correlation of BTMs, particularly CTX with
age, bilirubin levels, and hepatomegaly.
Categories: Internal Medicine, Pathology, Gastroenterology
Keywords: osteodystrophy, fibrosis, bone resorption, bone remodeling
Introduction
Osteoporosis is the most common bone disorder in patients suffering from chronic liver disease (CLD) and is
often known as hepatic osteodystrophy. Osteoporosis is an asymptomatic condition with decreased bone
mass, altered bone structure, and low bone strength, which may result in frequent fractures and leads
to significant morbidity in this population [1-2]. A literature review on osteoporosis in the Pakistani
population by AH Khan et al. showed that the prevalence of osteoporosis range from 5.6% to 17.8% in
premenopausal females and 20%-49.3% in postmenopausal females amongst the Pakistani population
[3]. CLD is considered a secondary cause of osteoporosis [4-5], as the liver plays a major role in the
production of various growth factors and hormones governing many metabolic activities affecting bone.
However, the burden of osteoporosis in patients suffering from CLD is not investigated in our population.
Chronic liver disease is one of the most common diseases with a worldwide increase in prevalence and a
high risk of irreversible tissue damage leading to cirrhosis. There are multiple etiologies like alcoholism,
chronic viral disease, excess tissue iron deposition, immunosuppressive therapy following liver
transplantation, etc. [6]. The prevalence of osteoporosis in patients with CLD is 30% to 40% worldwide [7-9].
The pathogenesis of a hepatic bone disease is multifaceted, complex, and difficult to understand but if
narrated in simple words, it occurs due to unstable bone remodeling with increased bone resorption and
decreased bone formation [10-13].
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Liver cirrhosis is associated with high mortality and morbidity. Particularly in developing countries like
Pakistan, the rate of progression of viral hepatitis to liver cirrhosis is high, with nearly 41%-52% cases of
hepatitis C virus and 30% with hepatitis B virus cases progressing to develop cirrhosis [14]. With therapeutic
improvement, the survival of CLD patients has increased, but so has the risk of extra-hepatic manifestations
such as osteoporosis. The literature on the status of bone turnover in CLD patients of our population is
scarce. The potential socioeconomic burden of developing osteoporosis with increased fracture risk in CLD
patients, in a country like Pakistan with a paucity of available health resources, is an enormous challenge
and needs increased awareness and early treatment. The current study aimed to determine the association
and correlation of bone turnover markers (BTMs) with biochemical markers in CLD patients.
Materials And Methods
It was a cross-sectional study conducted from January to October 2019 in known patients with chronic viral
hepatitis, registered at the gastroenterology clinic of Aga Khan University Hospital. Permission from the
ethical review committee of Aga Khan University Karachi, Pakistan (ERC # PAT-5105) was taken before the
initiation of the study. Only adults (18-65 years of age) with a history of viral hepatitis for more than six
months of duration were recruited. While patients with CLD due to any other cause other than viral
hepatitis were excluded.
Patients were recruited from the gastroenterology clinic, coming for a fibroscan analysis. Detailed clinical
history after informed consent was obtained on a structured questionnaire. Physical examination of patients
was performed to note the presence or absence of jaundice, hepatomegaly, ascites, and encephalopathy.
Eight to 10 milliliters of the non-fasting blood sample was drawn in serum separator tubes for biochemical
analysis of aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyl transferase
(GGT), cholesterol, albumin, total bilirubin, total alkaline phosphatase (ALP) and C-terminal telopeptide of
type-1 collagen (CTX). Serum total ALP was analyzed on Microlab 300 (ELItech Group, Puteaux, France)
using reagents by Merck & Co. ( Kenilworth, NJ) while serum CTX estimation was done on ADVIA Centaur
analyzer (Siemens Diagnostics, NY). All the rest of the biochemical analysis was done on ADVIA 1800
(Siemens Diagnostics). All samples were analyzed in batches with three levels of quality control material run
in each batch to validate the results. Patients were also assessed by the Fibroscan analyzer ((Echosens, Paris,
France) to determine the extent of fibrosis in the liver. A cutoff of 7.2 was used to identify fibrosis using
Fibroscan [15].
Statistical analysis
Data were analyzed in the Statistical Package of the Social Services (SPSS) version 21 (Copyright 1985-2015;
IBM Corp., Armonk, NY). The Shapiro-Wilk test was applied to check the hypothesis of normality for
quantitative (continuous) variables. Values are supposed to be offered as mean ± standard deviation or
median with interquartile range (IQR) for unceasing variables. Qualitative variables were presented by using
frequency and percentages. The Mann-Whitney U test was applied to compare the median difference of AST,
ALT, albumin, total bilirubin, ALP, and CTX in fibrosis versus non-fibrosis patients. Post-stratification
Spearman’s coefficients of correlation test applied to compare the association between both groups. The
bone turnover markers were compared with the degree of fibrosis assessed by Fibroscan.
Results
A total of 50 patients with a history of CLD for more than six months were included in this study, out of
which the majority were males (n=34, 68%), and 32% (n=16) were females. Forty-eight percent (n=24) of
patients were >40 years of age. The demographics and clinical and biochemical characteristics of patients
are further described in Table 1.
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Demographics Characteristics  n (%)
Male 34 (68%)
Age <40 years 26(52%)




Anti HCV positive 35(70%)
HBsAg positive 15(30%)
Elevated serum ALT (Reference range <45 IU/L)) 38(76%)
Elevated serum AST (Reference range<35IU/L) 37(74%)
Elevated serum GGT (Reference range <55IU/L) 21(42%)
Elevated serum total bilirubin (0.1-1.2 mg/dl) 6(12%)
Elevated serum direct bilirubin (0.0-0.3 mg/dl) 16(32%)
Elevated serum ALP (Reference range 45-129IU/L) ---
Elevated serum CTX (Reference 16-934 pg/ml) 2 (4%)
TABLE 1: Frequency distribution of clinical and biochemical characteristics of study subjects
with chronic hepatitis (n=50)
HCV: hepatitis C virus; ALT: alanine transaminase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; ALP: total alkaline
phosphatase; CTX: C-terminal telopeptide
There was an almost equal distribution of patients with fibrosis (n=24, 48%) and without fibrosis (n=26,
52%). The majority of the subjects had elevated liver enzymes. However, total ALP and CTX were within the
reference range in all subjects. Table 2 shows the comparison between groups with fibrosis and non-fibrosis.
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Study Variables Overall (n=50) Patients with fibrosis (n=24) Patients without fibrosis (n=26) p-value
Median age in years 40(50-30) 43(52.5-34.5) 38(46-29) 0.085
Median serum bilirubin total(mg/dl) 0.6(0.9-0.4) 0.6(0.95-0.4) 0.6(0.8-0.4) 0.747
Median serum albumin(g/dl) 3.6(4-3) 3.65(4.25-3) 3.55(4-3.2) 0.953
Median serum ALT(IU/L) 48(84-34) 56(89-42) 42.5(54-25) 0.045*
Median serum AST(IU/L) 39.5(49-30) 44(54.5-34) 36(45-25) 0.091
Median serum GGT(U/L) 30(68-15) 50(86-14.5) 26.5(56-15) 0.303
Median serum Cholesterol(mg/dl) 142(169-100) 102.5(147-99.5) 152(188-110) 0.006*
Median platelet count (no./mm3) 118.5(250-70) 68(102.5-50) 237.5(306-130) <0.001*
Median serum total ALP (IU/L) 91.5(103-82) 95(102-86) 85.5(103-75) 0.248
Median serum CTX (pg/ml) 240(340-210) 230(280-200) 280(490-210) 0.134
TABLE 2: Comparison of median levels of biochemical markers in liver disease and bone turnover
in patients with and without liver fibrosis
The Mann-Whitney U-test was applied, at a 95% confidence interval with a 5% level of significance; *p-value is statistically significant.
ALT: alanine transaminase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; ALP: total alkaline phosphatase; CTX: C-terminal
telopeptide
The median comparison showed platelet count, serum cholesterol, and serum ALT levels to be statistically
significant between the two groups. Median platelet count 68×109/L (102.5-50) and median cholesterol
levels 102.5 mg/dl (147-99.5) were decreased, whereas GGT levels were higher in patients with fibrosis.
Median levels of total ALP were 91.5 IU/L (103-82) and median levels of CTX were 240 pg/ml (340-210), and
the difference was statistically non-significant (Table 2). Table 3 describes the association of biochemical
markers with each other.
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 Cholesterol GGT Platelet Count Fibroscan ALT AST Total Bilirubin Albumin ALP CTX
Cholesterol 1.000 -.066 .418** -.501** -.008 .095 .055 -.158 .193 .161
GGT -.066 1.000 .109 .173 .227 .139 .176 -.146 .038 -.268
Platelet count .418** .109 1.000 -.820** -.184 -.084 .080 -.154 -.017 .104
Fibroscan -.501** .173 -.820** 1.000 .179 .023 -.032 .194 -.045 -.182
ALT -.008 .227 -.184 .179 1.000 .565** .303* -.264 .030 -.368**
AST .095 .139 .084 .023 .565** 1.000 .437** -.318* .020 -.243
Bilirubin total .055 .176 .080 -.032 .303* .437** 1.000 -.407** -.067 -.335*
Albumin -.158 -.146 -.154 .194 -.264 -.318* -.407** 1.000 -.267 .086
Alk phosphatase .193 .038 -.017 -.045 .030 .020 -.067 -.267 1.000 .082
CTX (ng/ml) .161 -.268 .104 -.182 -.368** -.243 -.335* .086 .082 1.000
TABLE 3: Spearman’s coefficients of correlation among CTX, alkaline phosphatase, Fibroscan,
and liver function markers
Correlation is significant at the 0.01 level (2-tailed)**
Correlation is significant at the 0.05 level (2-tailed)*
GGT: gamma-glutamyl transferase; ALT: alanine transaminase; AST: aspartate aminotransferase; ALP: total alkaline phosphatase; CTX: C-terminal
telopeptide
Liver enzymes, AST and ALT, showed a positive association with each other (r-value 0.56, p-value
<0.01). Poor correlation was noted between CTX and other biochemical markers. However, serum CTX
showed a weak inverse association that was statistically significant with ALT (r-value -0.36, p-value <0.01)
and total bilirubin (r-value -0.33, p-value <0.05).
Discussion
Literature reports that hepatitis B and C are associated with significantly reduced bone density
measurements even in the absence of cirrhotic changes. Viral hepatitis usually presents with increased
immune response and release of many resorption-activating cytokines, increasing the duration of liver
disease and deteriorating function, further enhancing bone resorption and hence increasing bone loss.
Treatment of viral hepatitis with interferon increases the complexity of understanding the cause of bone
loss in liver disease [16]. The pathogenesis of hepatic bone disease in patients with CLD is not exactly
known; there are multiple factors involved like deficiency of vitamin D and insulin-like growth factor (IGF-1)
[17-18], hyperbilirubinemia, and hypogonadism (estrogen and testosterone deficiency), which contribute to
bone loss in chronic liver disease.
Findings from the current study show that bone turnover markers (ALP and CTX) were within the reference
range in all the studied subjects suffering from chronic hepatitis. Even patients with fibrosis (diagnosed
using a Fibroscan cutoff of 7.2) showed values within the reference range. The results of this study also
depict that BTMs are not associated with the progression of liver disease or disease severity. CTX and
Fibroscan values showed a weak association (r -0.18, p-value >0.05).
Table 4 shows a comparison with other studies in which bone turnover was assessed in liver fibrosis
patients. In contrast to our study that shows no increase in bone turnover with normal total ALP and serum
CTX levels, bone turnover was found to be increased in all previous studies conducted by Guanabens,
Corazza G, George J, and Goral V et al. [19-22]. Normal CTX levels seem to have an association with our
population/ethnicity, as in another study conducted by ST Naeem et al., serum CTX levels were found to be
normal in postmenopausal Pakistani women with decreased bone mineral density (BMD) on dual-energy X-
ray absorptiometry (DXA) scan [23]. The reason for the normal to a very mild increase in CTX in our
population needs further investigation and CTX cannot be utilized to predict the development of liver
osteodystrophy in the Pakistani population.
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Country Authors Year Study subjects
Sample
size, n






with diabetes with NAFLD
in 3 groups: No-NAFLD,
patients with NAFLD and
fibrosis, patients with
NAFLD with no fibrosis
77
Bone formation inhibitors: NAFLD and fibrosis showed increased
sclerostin levels (54.1 ± 16.4 vs. 36.1 ± 11.9 vs. 42.3 ± 14.7 pmol/L) and
decreased serum DKK-1 (26.6 ± 17.8 vs. 49.0 ± 22.4 vs. 2.9 ± 19.4 
pmol/L). Resorption markers: NAFLD and fibrosis group had decreased
sCTX (0.16 ± 0.09 vs. 0.29 ± 0.17 vs. 0.40 ± 0.28 ng/mL) and increased
RANKL (0.04 ± 0.03 vs. 0.08 ± 0.06 vs. 0.11 ± 0.06 pmol/L) compared to
other groups.
Turkey Goral V et al 2010




Formation markers: Increased ALP 109.2 ± 57 IU/L, Decreased
osteocalcin 1.05 ± 2.5ng/ml, Resorption markers: Normal UDPD to






hepatitis leading to liver
cirrhosis
72
Formation markers: Normal ALP 138 ± 61 (132.7) IU&/L, Decreased
osteocalcin 2.99 ± 2.5 (1.8) ng/ml, Resorption markers: Increased UDPD





Viral hepatitis leading to
liver cirrhosis
68
Formation markers: Normal PICP (132 ± 36) ng/ml, increased osteocalcin





Liver fibrosis due to
primary biliary cirrhosis
34
Formation markers: Decreased osteocalcin (16.4 ± 1.2)ng/ml, increased
PICP (122.2 ± 5.9) and increased PINP (40.7 ± 5.3) ng/ml, Resorption
markers: Increased PYR (65.3 ± 4.4) nM/mM, increased DPYR (9.9 ± 1.1)
nM/mM, increased HYP (86.1 ± 6.9) nM/mg, increased NTX (68.9 ± 9.3)
nMBCE/mM, and increased CTX (213.5 ± 28.3) ug/mm
TABLE 4: Comparison with other studies regarding bone turnover status in chronic liver disease
NAFLD: non-alcoholic fatty liver disease; DKK-1: Dickkopf-related protein-1; RANKL: receptor activator of nuclear factor κβ ligand; PICP: carboxy-
terminal propeptide of type I procollagen; PINP: amino-terminal propeptide of type I procollagen; ALP: total alkaline phosphatase; ICTP: telopeptide
of type I collagen; TRAP: tartrate-resistant acid phosphatase; HYP: hydroxyproline; PYR: pyridinoline; DPYR: deoxypyridinoline; NTX: type I
collagen cross-linked N; CTX: C-telopeptide; UDPD: urinary deoxypyridinoline
There are certain limitations to the study. First, the sample size of the study was small, and another study
with a larger sample size in both groups (with and without fibrosis) is further needed. The current study was
not longitudinal and bone mineral density using DXA scans was not measured. The serum measurements
were taken at a single point thus could miss the associations between inflammatory markers, BTMs, i.e. ALP,
CTX, and Fibroscan findings, as the increased inflammatory response to viral infection can contribute to
more bone loss. The information about the stage of liver cirrhosis was not available. Additionally, more BTM
can be added in future studies to understand the clinical utility of these BTM in chronic hepatitis patients
who are at risk of hepatic osteodystrophy.
Conclusions
In the present study, no significant difference was found in the BTMs of patients with and without CLD.
However, there was a positive and significant correlation of BTMs, particularly CTX, with age, bilirubin
levels, and hepatomegaly. In conclusion, bone loss in liver disease is still under question, and the role of
BTMs for assessing early bone loss in liver disease is uncertain and needs further investigation. The role of




Human subjects: Consent was obtained or waived by all participants in this study. Ethical Review
committee of Aga Khan University Hospital issued approval PAT-5105. the Approval was given by the ERC
committee of Aga Khan University, Karachi, Pakistan. Animal subjects: All authors have confirmed that
this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE
uniform disclosure form, all authors declare the following: Payment/services info: All authors have
declared that no financial support was received from any organization for the submitted work. Financial
relationships: All authors have declared that they have no financial relationships at present or within the
previous three years with any organizations that might have an interest in the submitted work. Other
relationships: All authors have declared that there are no other relationships or activities that could appear
to have influenced the submitted work.
2021 Bukhari et al. Cureus 13(4): e14479. DOI 10.7759/cureus.14479 6 of 7
References
1. Sözen T, Özışık L, Başaran NC: An overview and management of osteoporosis . Eur J Rheumatol. 2017, 4:46-
56. 10.5152/eurjrheum.2016.048
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis
prevention, diagnosis, and therapy. JAMA. 2001, 285:785-795. 10.1001/jama.285.6.785
3. Khan AH, Jafri L, Ahmed S, Noordin S: Osteoporosis and its perspective in Pakistan: a review of evidence
and issues for addressing fragility fractures. Ann Med Surg. 2018, 29:19-25. 10.1016/j.amsu.2018.03.019
4. Muldowney FP, Neale G: Generalised disorders of bone associated with disease of the gastro-intestinal
tract. Ir J Med Sci. 1974, 143:57. 10.1007/BF02938127
5. Nakchbandi IA: Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic
implications. World J Gastroenterol. 2014, 20:9427-9438.
6. Handzlik-Orlik G, Holecki M, Wilczyński K, Duława J: Osteoporosis in liver disease: pathogenesis and
management. Ther Adv Endocrinol Metab. 2016, 7:128-135. 10.1177/2042018816641351
7. Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ: Osteoporosis in primary biliary
cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology. 1982, 83:97-102. 10.1016/S0016-
5085(82)80291-6
8. Cuthbert JA, Pak CYC, Zerwekh JE, Glass KD, Combes B: Bone disease in primary biliary cirrhosis: increased
bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology. 1984, 4:1-8.
10.1002/hep.1840040101
9. Stellon AJ, Webb A, Compston JE: Bone histomorphometry and structure in corticosteroid-treated chronic
active hepatitis. Gut. 1988, 29:378-384. 10.1136/gut.29.3.378
10. Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M: Hepatic osteodystrophy. Clin Cases Miner Bone
Metab. 2014, 11:185.
11. Crosbie OM, Freaney R, McKenna MJ, Hegarty JE: Bone density, vitamin D status, and disordered bone
remodeling in end-stage chronic liver disease. Calcified tissue international. 1999, 64:295-300.
10.1007/s002239900622
12. Collier JD, Ninkovic M, Compston JE: Guidelines on the management of osteoporosis associated with
chronic liver disease. Gut. 2002, 50:i1-i9. 10.1136/gut.50.suppl_1.i1
13. Gallego‐Rojo FJ, Gonzalez‐Calvin JL, Muñoz‐Torres M, Mundi JL, Fernandez‐Perez R, Rodrigo‐Moreno D:
Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis .
Hepatology. 1998, 28:695-699. 10.1002/hep.510280315
14. Memon MS, Zaki M: Burden of chronic liver disease and liver transplantation in Sindh . JLUMHS. 2013,
12:01.
15. Parikh P, Ryan JD, Tsochatzis EA: Fibrosis assessment in patients with chronic hepatitis B virus (HBV)
infection. Ann Transl Med. 2017, 5:40. 10.21037/atm.2017.01.28
16. Itoh Y, Okanoue T, Ohnishi N, et al.: Serum levels of soluble tumor necrosis factor receptors and effects of
interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1999, 94:1332-
1340. 10.1016/S0002-9270(99)00139-2
17. García-Fernández M, Castilla-Cortázar I, Díaz-Sanchez M, et al.: Antioxidant effects of insulin-like growth
factor-I (IGF-I) in rats with advanced liver cirrhosis. BMC Gastroenterol. 2005, 5:7. 10.1186/1471-230X-5-7
18. Arteh J, Narra S, Nair S: Prevalence of vitamin D deficiency in chronic liver disease . Digestive diseases and
sciences. 2010, 55:2624-2628. 10.1007/s10620-009-1069-9
19. Guañabens N, Parés A, Alvarez L, et al.: Collagen‐related markers of bone turnover reflect the severity of
liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res. 1998, 13:731-738.
20. Corazza GR, Trevisani F, Di Stefano M, et al.: Early increase of bone resorption in patients with liver
cirrhosis secondary to viral hepatitis. Dig Dis Sci. 2000, 45:1392-1399. 10.1023/A:1005568406664
21. George J, Ganesh HK, Acharya S, et al.: Bone mineral density and disorders of mineral metabolism in
chronic liver disease. World J Gastroenterol. 2009, 15:3516-3522. 10.3748/wjg.15.3516
22. Goral V, Simsek M, Mete N: Hepatic osteodystrophy and liver cirrhosis . World J Gastroenterol. 2010,
16:1639-1643. 10.3748/wjg.v16.i13.1639
23. Naeem ST, Hussain R, Raheem A, Siddiqui I, Ghani F, Khan AH: Bone turnover markers for osteoporosis
status assessment at baseline in postmenopausal Pakistani females. J Coll Physicians Surg Pak. 2016,
26:408-412.
2021 Bukhari et al. Cureus 13(4): e14479. DOI 10.7759/cureus.14479 7 of 7
